PIM3 and neoplasm: In addition, tumor-bearing mice treated with a combination of LV-Pim-3-shRNA plasmid and sorafenib showed a larger reduction in tumor burden (Figure 1G) and more aggressive decreases in tumor volume and weight than did those treated with PBS and sorafenib monotherapy (Figures 1H, I).